A Phase 2 Study to Investigate Sonrotoclax combined with Zanubrutinib Versus Zanubrutinib alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Overview

Sponsor-declared trial summary

Key facts

Sponsor

BeOne Medicines AG

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

27 Feb 2025 → ongoing

Decision date (initial)

2025-02-04

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

BeiGene Ltd.

External identifiers

EU CT number

2024-513970-23-00

ClinicalTrials.gov

NCT06637501

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Safety

To compare efficacy between Arm A (sonrotoclax plus
zanubrutinib) versus Arm B (zanubrutinib) measured
by the proportion of patients that achieve a complete
response (CR) or complete response with incomplete
bone marrow recovery (CRi)

Secondary objectives 3

1. To compare efficacy between Arm A (sonrotoclax plus zanubrutinib) versus Arm B (zanubrutinib) by rate of undetectable minimal residual disease at < 10-4 sensitivity (uMRD4)
2. To compare the efficacy between Arm A versus Arm B through CR/CRi per investigator response assessment; overall response rate (ORR), duration of response (DOR), and time to response (TTR) per IRC and investigator assessment; progression-free survival (PFS) per investigator assessment, and overall survival (OS).
3. To compare the safety and tolerability of Arm A (sonrotoclax plus zanubrutinib) versus Arm B (zanubrutinib)

Conditions and MedDRA coding

Previously Untreated Chronic Lymphocytic Leukemia

Regulatory references

Scientific advice from competent authorities

European Medicines Agency

Plan to share IPD

Yes

IPD plan description

BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 11

1. Previously untreated adult patient ≥ 18 years with a confirmed diagnosis of CLL that meets the iwCLL criteria (Hallek et al 2018). For those patients with a screening lymphocyte count < 5000 cells/μL, historical data confirming a lymphocyte count ≥ 5000 cells/μL at time of CLL diagnosis is required.
2. CLL requiring treatment as defined by ≥ 1 of the following criteria: a. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia. Hemoglobin concentrations < 10 g/dL or platelet counts < 100 x 109 cells/L are generally regarded as indications for treatment. b. Massive (ie, ≥ 6 cm below the left costal margin), progressive, or symptomatic splenomegaly. c. Massive (ie, ≥ 10 cm in longest diameter [LDi]), progressive or symptomatic lymphadenopathy. d. Progressive lymphocytosis with an increase of ≥ 50% over a 2-month period, or lymphocyte doubling time (LDT) < 6 months. Note: LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months; patients with initial blood lymphocyte counts < 30 x 109 cells/L may require a longer observation period to determine the LDT. Factors contributing to lymphocytosis other than CLL (eg, infections and steroid administration) should be excluded. e. Symptomatic or functional extranodal involvement (eg, skin, kidney, lung, and spine). f. Disease-related symptoms as defined by any of the following: − Unintentional weight loss ≥ 10% within the previous 6 months. − Fevers ≥ 100.5°F or ≥ 38.0°C for 2 or more weeks without evidence of infection. − Night sweats for ≥ 1 month without evidence of infection. − Significant fatigue (ie, ECOG Performance Status score of 2 or worse; cannot work or unable to perform usual activities). Note: Patients with significant fatigue cannot have an ECOG Performance Status score of 0.
3. ECOG Performance Status score of 0, 1, or 2.
4. Measurable disease by CT/MRI. Measurable disease is defined as ≥ 1 lymph node > 1.5 cm in LDi and measurable in 2 perpendicular diameters.
5. Adequate marrow function as defined by: a. Absolute neutrophil count ≥ 1.0 x 109 cells/L with an exception for patients with bone marrow involvement, in which case absolute neutrophil count must be ≥ 0.75 x 109 cells/L (without growth factor support within past 14 days). b. Platelet counts ≥ 75 x 109 cells/L; in cases of thrombocytopenia clearly due to marrow involvement of CLL (per the discretion of the investigator), platelet count should be ≥ 50 x 109 cells/L (without growth factor support or transfusion within past 14 days). c. Hemoglobin > 75 g/L (may be post-transfusion).
6. Adequate liver function as indicated by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values ≤ 2.5 x the institutional upper limits of normal (ULNs) value; serum total bilirubin < 3.0 x ULN (unless documented Gilbert’s syndrome).
7. Adequate renal function as defined as creatinine clearance ≥ 50 mL/min directly measured with a 24-hour urine collection or ≥ 50 mL/min/1.73 m2 calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) calculation (see Appendix 16 of the protocol).
8. Life expectancy > 6 months.
9. Signed informed consent and able to comply with the study protocol in the investigator’s judgment.
10. Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 90 days after the last dose of study drug (sonrotoclax and/or zanubrutinib). They must also have a negative serum pregnancy test result ≤ 7 days before randomization.
11. Nonsterile men must be willing to use a highly effective method of birth control and must refrain from donating sperm for the duration of the study and for ≥ 90 days after the last dose of study drug (sonrotoclax and/or zanubrutinib). Sterile male is defined as one for whom azoospermia has been previously demonstrated in a semen sample examination as definitive evidence of infertility. Males with known “low sperm counts” (consistent with “subfertility”) are not to be considered sterile for purposes of this study.

Exclusion criteria 23

1. Presence of del17p or known TP53 mutation.
2. Known prolymphocytic leukemia or history of, or currently suspected, Richter’s transformation (biopsy based on clinical suspicion may be needed to rule out transformation).
3. Known central nervous system involvement.
4. Received previous systemic treatment for CLL. Note: Up to 4 doses of anti-CD20 antibody specifically for autoimmune cytopenia is allowed; the last dose should have been given ≥ 6 months before screening.
5. Clinically significant cardiovascular disease including the following: a. Myocardial infarction within 6 months before screening. b. Unstable angina within 3 months before screening. c. New York Heart Association Class III or IV congestive heart failure (see Appendix 6 of the protocol). d. History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes). e. QTcF > 480 milliseconds based on Fridericia’s formula. − Note: QTcF value may be calculated as the numerical average of ≤ 3 separate readings for eligibility. f. History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place. g. Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mmHg at screening.
6. Severe or debilitating pulmonary disease, defined as chronic supplementation of oxygen and/or respiratory failure requiring assisted ventilation.
7. History of prior malignancy, except for conditions as listed below and as long as patient has recovered from the acute side effects incurred because of previous therapy: a. Malignancies surgically treated with curative intent and with no known active disease present for ≥ 3 years before randomization. b. Adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease. c. Adequately treated cervical carcinoma in situ without evidence of disease. d. Localized prostate cancer with Gleason score ≤ 6.
8. Active fungal, bacterial, and/or viral infection requiring systemic therapy.
9. Positive HIV serology (HIVAb) status or serologic status reflecting active hepatitis B or C infection as follows: a. Presence of hepatitis B surface antigen (HBsAg). b. Patients with presence of hepatitis B core antibody (HBcAb), in the absence of HBsAg, with detectable hepatitis B virus (HBV) DNA. − Note: The limit of detection for HBV DNA must have a sensitivity of < 20 IU/mL (see Section 8.1.3 of the protocol). Patients with presence of HBcAb but undetectable HBV DNA are eligible if they are willing to undergo HBV DNA monitoring every 4 weeks for HBV reactivation. c. Patients with the presence of hepatitis C virus (HCV) antibody and detectable HCV RNA. − Note: The limit of detection for HCV RNA must have a sensitivity of < 15 IU/mL (see Section 8.1.3 of the protocol. Patients with presence of HCVAb and undetectable HCV RNA are eligible if willing to undergo HCV RNA monitoring every 4 weeks for HCV reactivation.
10. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia requiring treatment.
11. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention.
12. History of stroke or intracranial hemorrhage ≤ 6 months before the first dose of study treatment.
13. Unable to swallow capsules or tablets or diseases significantly affecting GI function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
14. Hypersensitivity to zanubrutinib, sonrotoclax, or any of its excipients (eg, trehalose).
15. Receiving treatment with any moderate or strong CYP3A4 inhibitor (≤ 7 days or 5 half-lives, whichever is shorter) or strong CYP3A4 inducer (≤ 14 days or 5 half-lives, whichever is shorter) before the first dose of study drug, or requiring ongoing treatment with a moderate or strong CYP3A inhibitor or a strong CYP3A inducer.
16. Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit ≤ 3 days before the first dose of study drug.
17. At time of enrollment, receiving systemic corticosteroids, unless administered for adrenal replacement.
18. Vaccination with a live vaccine received for a minimum of 4 weeks before enrollment (see also prohibited medications, Section 6.9.2.2 of the protocol).
19. Use of investigational agents within the last 4 weeks before screening.
20. History of illicit drug use or alcohol abuse ≤ 12 months before randomization in the investigator’s judgment.
21. Pregnant and lactating females.
22. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator’s judgment, precludes the patient’s safe participation in the study.
23. Prisoners or patients who are institutionalized by regulatory or court order or persons who are in dependence to the sponsor or an investigator.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Best CR/CRi rate up to the first Post-Treatment Follow-up (PTFU1) Visit for Arm A and up to the C16D1 Visit for Arm B per Independent Review Committee (IRC) response assessment using the 2018 International Workshop on Chronic Lymphocytic Leukemia (Hallek et al 2018) guidelines with modification for treatment-related lymphocytosis (Cheson et al 2012) for patients with CLL

Secondary endpoints 3

1. uMRD4 rate measured in both peripheral blood and bone marrow aspirate at PTFU 1 Visit for Arm A and at C16D1 Visit for Arm B based on next-generation sequencing (NGS) (clonoSEQ®)
2. • CR/CRi rate per investigator response assessment • ORR per IRC and investigator response assessment • Landmark DOR event-free rate at 12 months per IRC response assessment • DOR per investigator response assessment • TTR per IRC and investigator response assessment • Landmark PFS rate at 24 months and overall PFS per investigator response assessment • OS
3. Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 and the iwCLL Grading Scale for Hematologic Toxicities in CLL Studies as appropriate. Tumor lysis syndrome (TLS) will be monitored per Howard criteria.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 5

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

BeOne Medicines AG

Sponsor organisation

BeOne Medicines AG

Address

Aeschengraben 27

City

Basel

Postcode

4051

Country

Switzerland

Scientific contact point

Organisation

BeOne Medicines AG

Contact name

BeOne Medical Officer

Public contact point

Organisation

BeOne Medicines AG

Contact name

BeOne Medical Officer

Third parties 15

Locations

3 EU/EEA countries · 13 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 30 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

7 submissions — initial application plus substantial / non-substantial modifications